Nasdaq:SCYX

JERSEY CITY, N.J., Dec. 20, 2021 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and…

JERSEY CITY, N.J., Dec. 03, 2021 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and…

JERSEY CITY, N.J., Dec. 01, 2021 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and…

JERSEY CITY, N.J., Nov. 29, 2021 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and…

Patients receiving one-day treatment with oral ibrexafungerp had significantly higher rates of clinical cure, mycological eradication, and clinical improvement at Day-10 compared to…

In the Phase 3 VANISH-303 study, ibrexafungerp demonstrated significantly higher rates of clinical cure and infection eradication versus placebo.Post hoc analysis found ibrexafungerp…

In vivo data demonstrated response rate for ibrexafungerp similar to current standard of care options for the treatment of mucormycosisCombination of ibrexafungerp with current therapies…

Company presentation will highlight BREXAFEMME® (ibrexafungerp tablets), the first FDA-approved product in the ibrexafungerp development pipeline, in addition to ongoing programs in the…